Immunovative Inc. Announces the Appointment of Dr. Laurence Terrisse-Rulleau to Business Advisory Board

August 15, 2012 |

4 min read

NEW YORK, NY--(Marketwire - August 15, 2012) -

Highlighted Links

Immunovative, Inc. (OTCBB: IMUN) (“IMUN” or the “Company”) announces today that it has appointed Dr. Laurence Rulleau, Ph.D. to its Business Advisory Board. The Business Advisory Board’s mandate is to assist the Company with management and guidance, developing strategies for raising capital, improving capital structure, identifying new opportunities and technical expertise in the biotechnology sector.

Dr. Rulleau has over ten years of experience as a sell-side biotech analyst covering the healthcare sector. In her experience as an analyst, Dr. Rulleau researched over 100 life sciences companies and was ranked the number one Canadian analyst by the Starmine survey (a Thomson Reuters Company). Dr. Rulleau was involved in numerous transactions to help put in place strategic and financing plans. Dr. Rulleau has worked for Blackmont Capital, Orion Securities, Desjardins Securities and Laurentian Bank. Dr. Rulleau has a Masters in Biology from The Université du Québec à Montréal (UQAM) and a Ph.D. from Montreal Clinical Research Institute. She is the author of numerous scientific papers in peer review journals and presented at worldwide scientific conventions.

Chairman of the Business Advisory Board, Bruno Vanderschelden stated, “I am particularly impressed with the credentials and experiences of Dr. Rulleau. Not only does she have the scientific background to assist the Company, she also has been an analyst at some of the largest international brokerage houses. She will certainly provide the Company with an unmatched insight within the biotech sector. I look forward to working closely with Dr. Rulleau.”

“Dr. Rulleau brings unrivaled experience and visionary leadership to the Company. She will act as a sounding board, and share best practices and lessons learned from her experience and knowledge. Dr. Rulleau will be an integral member of the Advisory Board and we whole-heartedly welcome her on board,” stated Antonio Treminio, Chairman and Chief Executive Officer of IMUN.

Dr. Rulleau stated, “I am very pleased to join the business advisory board of IMUN. In my career both as a researcher and in the business analysis of new medical products, I have always had a particular interest in cancer and alternatives to chemotherapy. After conducting my own technical due diligence on IMUN, including an in depth technical interview with the inventor of the IMUN technology, and review of the pre-clinical and clinical data, I concluded that this technology is novel. I look forward with great enthusiasm to using my background and experience to assist IMUN in growing into an international biopharmaceutical company.”

About Immunovative, Inc.:
On December 12, 2011, Immunovative, Inc. (“IMUN”) signed an exclusive License Agreement (the “License Agreement”) with Immunovative Therapies, Ltd. (“ITL”). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL’s current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN’s website at www.imun.com.

DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.